Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Concerns About Vape Addiction, Injury Provide Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) with Opportunity

  • Lexaria Bioscience continues to advance the effectiveness of its proprietary DehydraTECH technology, a formulation that teams with drug substances such as nicotine and cannabidiol to quickly carry those drugs into a user’s blood stream
  • Recent concerns about the safety of vape products and ongoing concerns about the safety of tobacco are opening doors to Lexaria’s edible technology
  • Newly legalized cannabis-infused edibles began hitting store shelves nationwide in Canada last month, presenting Lexaria with new potential licensing outlets for its increasingly effective products

If 2019 was the year when vape users discovered the potential perils of using untested off-brand products, 2020 may well be the year when vape users share the common woe of struggling to beat an addiction.

The U.S. Centers for Disease Control and Prevention (CDC) reported at year’s end that 2,561 people had been hospitalized with the vape-related lung illness now known as ‘e-cigarette or vaping product use-associated lung injury’ (EVALI) as of December 27, that the illness had afflicted every U.S. state and two territories, and that 55 EVALI-related deaths had been confirmed in 27 states and the District of Columbia, with the incidence of new cases in decline (

With the advent of the new year, anti-youth vaping advocacy group Truth Initiative reported ( a survey that showed “nearly half of young people are looking to quit vaping as their New Year’s resolution.” Many parents find themselves fighting back fears of the potential outcomes as they see their children drawn into addictive behaviors (

Oral drug product innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a company dedicated to the concept that there are better alternative methods for drug substance use than inhalation. The British Columbia-based bio-delivery technology developer patented its DehydraTECH™ oral drug delivery technology and has been continuing to advance its ability to pair the IP with substances such as nicotine and cannabidiol (CBD) for access to users’ bloodstreams at rapid rates comparable to the speed of acquisition by inhalation.

Swallowed medications have historically been slower to provide effective action than inhaled ones, leading substance users looking for a quick fix to lean toward the latter. But the deleterious and deadly consequences of smoking tobacco products have been publicly acknowledged for decades, though hardly stemming the tide of nicotine addiction as one generation succeeds another.

The continued preference for the rapid delivery of inhaled drug substances has led many researchers to seek alternatives beyond deterrence campaigns. DehydraTECH’s newest formulation was recently shown to deliver to deliver 811 percent more CBD into the bloodstream than generic industry control formulations, nearly doubling the capacity of existing DehydraTECH technology. It was additionally shown to deliver 1,937 percent more CBD across the blood-brain barrier into brain tissue than generic industry control formulations and 487 percent more than the original DehydraTECH technology (

The blood-brain barrier is a natural biological system of blood vessels and endothelial cells that bar nearly all small-molecule drugs from accessing the brain’s central nervous system hierarchy and finding the ability to defeat it has been a primary concern for medical product developers.

The potential applications of Lexaria’s technology are many. Perhaps most noticeable at the moment is the uses arising from the legalization of cannabis-infused food on a national basis in Canada, with the first products in store shelves as of last month (, but the technology also creates the potential for vape makers to offer non-inhaled products to shore up their marketing.

The company has begun licensing its technology to a variety of other producers in the cannabis and tobacco spaces. Lexaria’s licensed in-house research laboratory and its IP portfolio have developed 16 patents with over 60 patents pending worldwide.

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit

MissionIR (MIR)
Atlanta, Georgia
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published:

This entry was posted in Lexaria Bioscience Corp. (LXRP). Bookmark the permalink.

Comments are closed.